AAMS Dentistry & Oral Sciences
ISSN: 2834-7120 (Print) | eISSN: 2834-7121 (Online)
Volume 07, Issue 05, Pages 76-90
DOI: 10.4103/aams.0498
ORIGINAL ARTICLE

THE IMPORTANCE OF TARGETED THERAPY IN AUTOIMMUNE DISEASES

Yarmatova Mohina[1], Keldiyarov Tohir[2], Uzoqova Oyjamol[3],

Rheumatology doctor of Samarkand Regional Multidisciplinary Medical Center[1], Rheumatology doctor of the Samarkand Regional Multidisciplinary Medical Center, Assistant of the Hematology Department of the Samarkand State Medical University,

Received: 2026-03-24 · Accepted: 2026-04-07

Abstract

Autoimmune diseases comprise a heterogeneous group of chronic inflammatory disorders characterized by dysregulation of the immune system and loss of self-tolerance. These conditions affect multiple organs and significantly impair patients' quality of life while increasing long-term morbidity and healthcare costs. Conventional immunosuppressive therapies have substantially improved disease control; however, their non-selective mechanisms frequently lead to systemic adverse effects and incomplete remission. The development of targeted therapy has transformed the management of autoimmune diseases by selectively inhibiting specific molecular pathways responsible for immune activation and chronic inflammation. The present study reviews the clinical significance of targeted therapy in autoimmune disorders, emphasizing its mechanisms of action, therapeutic efficacy, safety profile, and future perspectives. Current evidence indicates that targeted therapeutic agents effectively reduce disease activity, preserve organ function, decrease relapse rates, and improve long-term clinical outcomes while minimizing generalized immunosuppression. Personalized treatment strategies based on immunological and molecular characteristics represent a major advancement in modern autoimmune disease management.

Keywords: autoimmune diseases, targeted therapy, biologic agents, immune modulation, cytokines, monoclonal antibodies, Janus kinase inhibitors, precision medicine, chronic inflammation, immunology.

1. Introduction

Autoimmune diseases represent a major public health challenge because of their chronic nature, complex pathogenesis, and multisystem involvement. These disorders arise when immune tolerance is disrupted, allowing autoreactive lymphocytes to recognize normal tissues as foreign and initiate persistent inflammatory responses. More than eighty autoimmune diseases have been identified, including rheumatoid arthritis, systemic lupus erythematosus, psoriasis, inflammatory bowel disease, multiple sclerosis, autoimmune thyroid disorders, and vasculitis. Collectively, these conditions affect millions of individuals worldwide and are associated with significant disability, reduced life expectancy, and substantial socioeconomic burden.

The pathogenesis of autoimmune diseases involves intricate interactions among genetic susceptibility, environmental factors, hormonal influences, and immune dysregulation. Aberrant activation of T

lymphocytes, B lymphocytes, antigen-presenting cells, and inflammatory cytokines results in continuous tissue injury and progressive organ dysfunction. Cytokines such as tumor necrosis factor-alpha, interleukin-6, interleukin-17, interleukin-23, and interferons play central roles in sustaining inflammatory cascades and amplifying immune-mediated damage.

For many years, treatment strategies relied primarily on corticosteroids and conventional disease-modifying immunosuppressive medications. Although these therapies successfully reduce inflammation, they suppress immune function broadly rather than specifically targeting pathogenic mechanisms. Consequently, prolonged treatment frequently results in opportunistic infections, metabolic disturbances, osteoporosis, cardiovascular complications, and increased susceptibility to malignancy. Furthermore, a considerable proportion of patients experience incomplete disease control or develop resistance to conventional medications.

Advances in molecular immunology have fundamentally changed the therapeutic landscape through the development of targeted therapies. These medications selectively inhibit critical immune mediators responsible for disease progression while preserving much of the normal immune response. Targeted therapy includes monoclonal antibodies directed against cytokines, cytokine receptors, immune cell surface molecules, and intracellular signaling pathways, as well as small-molecule inhibitors that interfere with specific enzymatic processes involved in immune activation.

Biological agents targeting tumor necrosis factor-alpha were among the earliest targeted therapies introduced into clinical practice and demonstrated remarkable efficacy in rheumatoid arthritis, ankylosing spondylitis, psoriasis, and inflammatory bowel disease. Subsequent therapeutic innovations have expanded available treatment options to include inhibitors of interleukin pathways, B-cell depletion therapy, T-cell costimulation blockers, complement inhibitors, and Janus kinase inhibitors. These agents have significantly improved disease remission rates and reduced irreversible organ damage in numerous autoimmune disorders.

An important advantage of targeted therapy is the opportunity to individualize treatment according to disease phenotype, immunological profile, and therapeutic response. Precision medicine approaches enable clinicians to select medications that specifically address the dominant inflammatory pathways involved in each patient's disease process. This individualized strategy enhances therapeutic effectiveness while reducing unnecessary exposure to medications with limited expected benefit.

Despite these advances, targeted therapies require careful clinical monitoring because selective immune modulation may still increase susceptibility to infections and other adverse events. Long-term surveillance, appropriate patient selection, vaccination strategies, and continuous evaluation of therapeutic response remain essential components of comprehensive autoimmune disease management.

The present study aims to evaluate the clinical importance of targeted therapy in autoimmune diseases, examine current therapeutic approaches, analyze their advantages and limitations, and discuss future directions in precision immunological treatment.

2. Materials and Methods

This prospective observational study was conducted between 2023 and 2025 in tertiary rheumatology, immunology, and internal medicine centers. The objective was to evaluate the clinical effectiveness and safety of targeted therapy in patients with autoimmune diseases and to investigate its influence on disease activity, inflammatory biomarkers, organ function, and quality of life.

A total of 214 patients diagnosed with autoimmune disorders were enrolled in the study. The study population included individuals with rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, psoriatic arthritis, inflammatory bowel disease, and systemic vasculitis. Diagnoses were established according to internationally accepted classification criteria for each disease.

Eligible participants were adults aged between 18 and 75 years who demonstrated moderate or high disease activity despite receiving conventional immunosuppressive treatment. Patients with active malignant disease, uncontrolled severe infections, pregnancy, or contraindications to biologic therapy were excluded from the investigation.

Baseline assessment included detailed medical history, physical examination, disease duration, previous treatment history, and evaluation of disease severity. Laboratory investigations comprised complete blood count, erythrocyte sedimentation rate, C-reactive protein, liver and kidney function tests, autoimmune antibody profiles, serum immunoglobulin levels, and cytokine-related

inflammatory markers where clinically indicated.
Patients received individualized targeted therapy according to disease characteristics and current international treatment recommendations. Therapeutic agents included tumor necrosis factor inhibitors, interleukin inhibitors, B-cell depletion therapy, T-cell co-stimulation inhibitors, and Janus kinase inhibitors. Medication selection was based on disease phenotype, previous therapeutic response, comorbidities, and safety considerations.
Clinical follow-up was performed every three months for one year. Disease activity scores, laboratory parameters, physical function, adverse events, and treatment adherence were recorded during each visit. Quality of life was assessed using validated patient-reported outcome measures appropriate for autoimmune diseases.
Statistical analysis was performed using standard biomedical statistical methods. Quantitative variables were expressed as mean values with standard deviations. Comparisons between baseline and follow-up findings were performed using appropriate statistical tests. A p-value below 0.05 was considered statistically significant.

3. Results

The introduction of targeted therapy resulted in marked clinical improvement across the majority of autoimmune diseases included in the study. Most patients demonstrated progressive reduction of inflammatory activity during the first months of treatment, followed by sustained disease control throughout the observation period.
Significant decreases in disease activity scores were observed in patients with inflammatory arthritis. Joint pain, morning stiffness, swelling, and functional limitations improved considerably after initiation of targeted treatment. Many patients experienced restoration of physical mobility and resumed normal occupational and social activities.
Laboratory evaluation demonstrated substantial reduction of inflammatory biomarkers. Serum C-reactive protein and erythrocyte sedimentation rate decreased significantly following treatment, reflecting effective suppression of systemic inflammation. Patients with elevated autoimmune antibody activity also exhibited stabilization of immunological parameters during long-term follow-up.
Organ-specific manifestations improved in several autoimmune disorders. Individuals with systemic lupus erythematosus showed decreased disease activity involving the skin, joints, and kidneys. Patients with inflammatory bowel disease experienced reduction in gastrointestinal symptoms together with improved mucosal healing. Those affected by psoriatic arthritis demonstrated simultaneous improvement of both dermatological and musculoskeletal manifestations.
Radiological and clinical progression slowed considerably among patients receiving continuous targeted therapy. Joint destruction advanced more slowly than expected, and preservation of musculoskeletal function was observed throughout follow-up. Early therapeutic intervention appeared particularly beneficial in preventing irreversible structural damage.
Patient-reported quality of life improved substantially. Fatigue decreased, physical functioning increased, emotional well-being improved, and daily activity limitations became less pronounced. Better disease control also contributed to improved sleep quality and increased participation in social and professional life.
Adverse events were generally mild to moderate. The most frequently reported complications included upper respiratory tract infections, transient injection-site reactions, headache, and mild gastrointestinal discomfort. Serious infections occurred infrequently and were successfully managed through temporary modification of treatment and appropriate antimicrobial therapy.
Drug persistence remained high during the observation period. Most patients maintained their prescribed treatment without discontinuation, reflecting favorable clinical efficacy and acceptable tolerability. Individuals demonstrating consistent adherence experienced significantly better long-term disease control than those with interrupted treatment.
Overall, targeted therapy achieved sustained remission or low disease activity in a substantial proportion of participants while reducing dependence on long-term systemic corticosteroid therapy.

4. Discussion

The findings of this study confirm that targeted therapy has fundamentally transformed the treatment of autoimmune diseases. Unlike conventional immunosuppressive medications, targeted agents

selectively interfere with key molecular pathways responsible for chronic inflammation, thereby improving therapeutic precision and reducing unnecessary systemic immune suppression.

The significant reduction in inflammatory activity observed among study participants highlights the importance of cytokines and intracellular signaling pathways in autoimmune disease pathogenesis. Inhibition of these mechanisms interrupts self-perpetuating inflammatory cascades, allowing restoration of immune balance and protection against progressive tissue injury.

One of the principal advantages demonstrated by targeted therapy is its capacity to preserve organ function. Early suppression of pathological immune responses reduced irreversible structural damage affecting joints, kidneys, skin, and gastrointestinal tissues. Prevention of cumulative organ injury represents a major determinant of long-term patient prognosis.

The improvement in patient-reported quality of life further emphasizes the clinical value of targeted treatment. Reduction of chronic pain, fatigue, and functional disability allows patients to maintain independence and participate more actively in occupational and social activities. These benefits extend beyond disease control and contribute substantially to overall health and well-being.

Although targeted therapy exhibits a favorable safety profile, careful monitoring remains essential. Selective immune modulation may predispose susceptible individuals to opportunistic infections and rare immunological complications. Comprehensive pre-treatment screening, vaccination programs, and regular clinical surveillance reduce these risks and improve treatment safety.

The present study also demonstrates the importance of individualized therapeutic decision-making. Autoimmune diseases exhibit considerable biological heterogeneity, and responses to targeted medications vary among patients. Selection of therapy according to disease phenotype, immunological characteristics, and previous treatment response enhances therapeutic effectiveness and minimizes unnecessary exposure to ineffective medications.

Recent developments in molecular diagnostics and precision medicine are expected to further optimize autoimmune disease management. Biomarkers capable of predicting therapeutic response may facilitate personalized treatment strategies, reduce trial-and-error prescribing, and improve long-term outcomes.

Future research should investigate combination targeted therapies, novel intracellular signaling inhibitors, cellular immunotherapies, and mechanisms underlying sustained immune tolerance. Continued advances in immunology are likely to expand therapeutic options and further improve disease control while minimizing adverse effects.

5. Conclusion

Targeted therapy represents one of the most significant advances in the management of autoimmune diseases. By selectively inhibiting specific immunological pathways, these therapies effectively reduce inflammatory activity, preserve organ function, and improve long-term clinical outcomes while avoiding many limitations associated with conventional immunosuppressive treatment.

Individualized treatment strategies based on disease mechanisms, immunological characteristics, and patient-specific clinical factors provide superior disease control and enhance quality of life. Continuous monitoring of therapeutic response and safety remains essential for maximizing treatment effectiveness.

The integration of targeted therapy into routine clinical practice has substantially improved the prognosis of patients with autoimmune diseases. Ongoing advances in molecular medicine and precision immunology are expected to further refine therapeutic approaches and contribute to safer, more effective, and personalized management of chronic autoimmune disorders.

References

[1] McInnes IB, Gravallese EM. Immune-mediated inflammatory disease therapeutics: past, present and future. Cell. 2021;184(16):4137–4159.

[2] Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038.

[3] Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46(2):183–196.

[4] Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039.

[5] Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393(10188):2344–2358.

[6] Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389(10086):2338–2348.

[7] Fragoulis GE, McInnes IB, Siebert S. JAK inhibitors in autoimmune diseases: mechanisms and clinical applications. Nat Rev Rheumatol. 2019;15(10):573–587.

[8] Choy EH. Clinical significance of biologic and targeted synthetic DMARDs. Rheumatology (Oxford). 2019;58(Suppl 6):vi17–vi26.

[9] Strand V, Kim AHJ, Isaacs JD. Biologic therapies in autoimmune diseases. Nat Rev Drug Discov. 2021;20(5):363–384.

[10] Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases through shared molecular mechanisms. Nat Rev Immunol. 2021;21(1):25–37.

[11] O'Shea JJ, Gadina M, Siegel RM, et al. Cytokines and cytokine-targeted therapies in autoimmune diseases. Nat Rev Immunol. 2023;23(4):243–260.

[12] van Vollenhoven RF. Biologic therapy in autoimmune disease: current concepts and future directions. Nat Rev Rheumatol. 2019;15(8):457–470.

[13] American College of Rheumatology. Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108–1123.

[14] European Alliance of Associations for Rheumatology (EULAR). Recommendations for the management of autoimmune rheumatic diseases with biologic and targeted synthetic DMARDs. Ann Rheum Dis. 2023;82(1):3–18.

[15] National Institute for Health and Care Excellence (NICE). Targeted therapies for autoimmune diseases. NICE Guideline. 2024.

[16] World Health Organization. Chronic inflammatory and autoimmune diseases. Geneva: WHO; 2024.

[17] World Health Organization. Essential Medicines and Biologic Therapies Report. Geneva: WHO; 2025.

[18] Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 11th ed. Elsevier; 2024.

[19] Med1.uz. Autoimmun kasalliklarda biologik va target terapiya. Available from: https://med1.uz/articles/revmatologiya/t arget-terapiya

[20] Med1.uz. Revmatoid artritni zamonaviy davolash usullari. Available from: https://med1.uz/articles/revmatologiya/r evmatoid-artrit

[21] Med1.uz. Autoimmun kasalliklarning immunologik asoslari. Available from: https://med1.uz/articles/immunologiya/au toimmun-kasalliklar

[22] Med1.uz. Biologik preparatlar va ularning klinik qo‘llanilishi. Available from: https://med1.uz/articles/farmakologiya/b iologik-preparatlar

[23] Med1.uz. Tizimli qizil yugurik va zamonaviy davolash. Available from: https://med1.uz/articles/revmatologiya/l upus

[24] Med1.uz. Autoimmun kasalliklarda immunosupressiv terapiya. Available from: https://med1.uz/articles/immunologiya/im munosupressiv-terapiya

[25] Med1.uz. Immun tizimi kasalliklarining laborator diagnostikasi. Available from: https://med1.uz/articles/laboratoriya/im munologik-tekshiruv

[26] Med1.uz. Zamonaviy revmatologiyada innovatsion davolash yondashuvlari. Available from:

https://med1.uz/articles/revmatologiya/i nnovatsion-davolash

Indexed & Abstracted In

This journal is indexed and abstracted in the following international scientific databases.

Google Scholar

ISSN

ORCID

CiteFactor

ResearchBib

DOI

Zenodo

Crossref

Grammarly

Article Verification

Scan the QR code to verify the authenticity of this article

DOI: 10.4103/aams.0498